Increased levels of YAP-1 and Epidermal Growth Factor Receptor (EGFR) activation have been previously reported to be compensatory mechanisms to KRAS inhibition in pancreatic cancer cells (Vartanian et al, 2013; Kapoor et al, 2014). This evidence concerns the gene YAP1 and pancreatic neoplasm.